Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158262 · ClinicalTrials.gov registry record · Phase 4
Effect of Propranolol on Preventing Posttraumatic Stress Disorder
A Phase 4 study of Post Traumatic Stress Disorder, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 2
- Study locations
NCT00158262: Completed Phase 4 study of Post Traumatic Stress Disorder, sponsored by Massachusetts General Hospital.
NCT00158262 is a Phase 4 study of Post Traumatic Stress Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 43 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00158262, a Phase 4 study of Post Traumatic Stress Disorder, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will assess the effectiveness of taking propranolol soon after a traumatizing incident in reducing the incidence and severity of posttraumatic stress disorder in acutely traumatized individuals.
Primary Outcome
The posterior probability of developing PTSD was determined for each participant from a composite of psychophysiological responses during script-driven mental imagery of traumatic events (two exemplars) that included assessments of heart rate response in beats per minute, skin conductance response in microSiemens, and corrugator and left lateral frontalis facial muscle electromyogram (EMG) responses in microVolts. Responses for the two traumatic scripts were averaged and square-root transformed
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Propranolol
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
What the finished NCT00158262 record still lists
NCT00158262 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00158262 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00158262 about?
NCT00158262 is a clinical study titled "Effect of Propranolol on Preventing Posttraumatic Stress Disorder". This study will assess the effectiveness of taking propranolol soon after a traumatizing incident in reducing the incidence and severity of posttraumatic stress disorder in acutely traumatized individuals.
What is the current status of trial NCT00158262?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2004-09. Estimated completion is 2008-05.
What conditions does trial NCT00158262 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT00158262?
The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG).
Who is sponsoring clinical trial NCT00158262?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00158262 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00158262's enrollment target sits among peer trials
43 184th of 262 higher than 79 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder
RECRUITING · Phase 4
-
An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
RECRUITING · Phase 4
-
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD
ACTIVE NOT RECRUITING · Phase 4
-
Short Course Glucocorticoid Treatment for PTSD
COMPLETED · Phase 4
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
-
A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia